NPM1 and acute myeloid leukemia: We were not able to perform the mutation screening in samples collected before the diagnosis of AML in our patient population to determine whether DNMT3A mutations may have preexisted in the patients whose samples showed a discrepancy between DNMT3A and NPM1 mutation MRD levels.